Hannah Y Wen1, Melissa Krystel-Whittemore2, Sujata Patil3, Fresia Pareja1, Zenica L Bowser1, Maura N Dickler4, Larry Norton4, Monica Morrow5, Clifford A Hudis4, Edi Brogi1. 1. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. 2. The University of Kansas Medical Center, Kansas City, Kansas. 3. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. 4. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 5. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Abstract
BACKGROUND: A 21-gene expression assay (Oncotype DX recurrence score [RS]) that uses reverse transcriptase-polymerase chain reaction is used clinically in patients with early-stage, estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast carcinoma (ER+/HER2- BC) to determine both prognosis with tamoxifen therapy and the usefulness of adding adjuvant chemotherapy. Use of the assay is associated with reductions in overall chemotherapy use. The current study examined the treatments and outcomes in patients with low RS. METHODS: The authors reviewed the institutional database to identify patients with lymph node-negative, ER+/HER2- BC who were treated at the study institution between September 2008 and August 2013 and their 21-gene RS results. RESULTS: A total of 1406 consecutive patients with lymph node-negative ER+/HER2- BC and a low RS were identified (510 patients had an RS of 0-10 and 896 patients had an RS of 11-17). The median age at the time of diagnosis of BC was 56 years; 63 patients (4%) were aged <40 years. Overall, 1361 patients (97%) received endocrine therapy and 170 patients (12%) received chemotherapy. The median follow-up was 46 months. Six patients (0.4%) developed distant metastases (1 patient with an RS of 5 and 5 patients with an RS of 11-17). In the cohorts of patients with an RS of 11 to 17, the absolute rate of distant metastasis among patients aged <40 years was 7.1% (3 of 42 patients) versus 0.2% among patients aged ≥40 years (2 of 854 patients). CONCLUSIONS: The data from the current study document a 0.4% rate of distant metastasis within 5 years of BC diagnosis among patients with lymph node-negative ER+/HER2- BC with an RS <18. Patients aged <40 years at the time of BC diagnosis were observed to have a higher rate of distant metastases. Analysis of data from other studies is necessary to validate this observation further. Cancer 2017;131-137.
BACKGROUND: A 21-gene expression assay (Oncotype DX recurrence score [RS]) that uses reverse transcriptase-polymerase chain reaction is used clinically in patients with early-stage, estrogen receptor (ER)-positive, humanepidermal growth factor receptor 2 (HER2)-negative breast carcinoma (ER+/HER2- BC) to determine both prognosis with tamoxifen therapy and the usefulness of adding adjuvant chemotherapy. Use of the assay is associated with reductions in overall chemotherapy use. The current study examined the treatments and outcomes in patients with low RS. METHODS: The authors reviewed the institutional database to identify patients with lymph node-negative, ER+/HER2- BC who were treated at the study institution between September 2008 and August 2013 and their 21-gene RS results. RESULTS: A total of 1406 consecutive patients with lymph node-negative ER+/HER2- BC and a low RS were identified (510 patients had an RS of 0-10 and 896 patients had an RS of 11-17). The median age at the time of diagnosis of BC was 56 years; 63 patients (4%) were aged <40 years. Overall, 1361 patients (97%) received endocrine therapy and 170 patients (12%) received chemotherapy. The median follow-up was 46 months. Six patients (0.4%) developed distant metastases (1 patient with an RS of 5 and 5 patients with an RS of 11-17). In the cohorts of patients with an RS of 11 to 17, the absolute rate of distant metastasis among patients aged <40 years was 7.1% (3 of 42 patients) versus 0.2% among patients aged ≥40 years (2 of 854 patients). CONCLUSIONS: The data from the current study document a 0.4% rate of distant metastasis within 5 years of BC diagnosis among patients with lymph node-negative ER+/HER2- BC with an RS <18. Patients aged <40 years at the time of BC diagnosis were observed to have a higher rate of distant metastases. Analysis of data from other studies is necessary to validate this observation further. Cancer 2017;131-137.
Authors: Jennifer E Joh; Nicole N Esposito; John V Kiluk; Christine Laronga; M Catherine Lee; Loretta Loftus; Hatem Soliman; Judy C Boughey; Carol Reynolds; Thomas J Lawton; Peter I Acs; Lucio Gordan; Geza Acs Journal: Oncologist Date: 2011-10-20
Authors: Laura J van 't Veer; Hongyue Dai; Marc J van de Vijver; Yudong D He; Augustinus A M Hart; Mao Mao; Hans L Peterse; Karin van der Kooy; Matthew J Marton; Anke T Witteveen; George J Schreiber; Ron M Kerkhoven; Chris Roberts; Peter S Linsley; René Bernards; Stephen H Friend Journal: Nature Date: 2002-01-31 Impact factor: 49.962
Authors: Michaela A Dinan; Xiaojuan Mi; Shelby D Reed; Bradford R Hirsch; Gary H Lyman; Lesley H Curtis Journal: JAMA Oncol Date: 2015-05 Impact factor: 31.777
Authors: Foluso O Ademuyiwa; Austin Miller; Tracey O'Connor; Stephen B Edge; Mangesh A Thorat; George W Sledge; Ellis Levine; Sunil Badve Journal: Breast Cancer Res Treat Date: 2011-01-01 Impact factor: 4.872
Authors: Lyndsay Harris; Herbert Fritsche; Robert Mennel; Larry Norton; Peter Ravdin; Sheila Taube; Mark R Somerfield; Daniel F Hayes; Robert C Bast Journal: J Clin Oncol Date: 2007-10-22 Impact factor: 44.544
Authors: Mark N Levine; Jim A Julian; Philippe L Bedard; Andrea Eisen; Maureen E Trudeau; Brian Higgins; Louise Bordeleau; Kathleen I Pritchard Journal: J Clin Oncol Date: 2015-11-23 Impact factor: 44.544
Authors: Scott D Ramsey; William E Barlow; Ana M Gonzalez-Angulo; Sean Tunis; Laurence Baker; John Crowley; Patricia Deverka; David Veenstra; Gabriel N Hortobagyi Journal: Contemp Clin Trials Date: 2012-09-18 Impact factor: 2.226
Authors: Shelly S Lo; Patricia B Mumby; John Norton; Karen Rychlik; Jeffrey Smerage; Joseph Kash; Helen K Chew; Ellen R Gaynor; Daniel F Hayes; Andrew Epstein; Kathy S Albain Journal: J Clin Oncol Date: 2010-01-11 Impact factor: 44.544
Authors: Michael J Hassett; Samuel M Silver; Melissa E Hughes; Douglas W Blayney; Stephen B Edge; James G Herman; Clifford A Hudis; P Kelly Marcom; Jane E Pettinga; David Share; Richard Theriault; Yu-Ning Wong; Jonathan L Vandergrift; Joyce C Niland; Jane C Weeks Journal: J Clin Oncol Date: 2012-05-14 Impact factor: 44.544
Authors: Balázs Győrffy; Christos Hatzis; Tara Sanft; Erin Hofstatter; Bilge Aktas; Lajos Pusztai Journal: Breast Cancer Res Date: 2015-01-27 Impact factor: 6.466
Authors: Eva Jezkova; Pavol Zubor; Karol Kajo; Marian Grendar; Karol Dokus; Marian Adamkov; Zora Lasabova; Lukas Plank; Jan Danko Journal: Oncol Lett Date: 2017-05-18 Impact factor: 2.967
Authors: Marie Alexandre; Aurélie Maran-Gonzalez; Marie Viala; Nelly Firmin; Véronique D'Hondt; Marian Gutowski; Céline Bourgier; William Jacot; Séverine Guiu Journal: Cancer Manag Res Date: 2019-12-11 Impact factor: 3.989
Authors: James Brierley; Brian O'Sullivan; Hisao Asamura; David Byrd; Shao Hui Huang; Anne Lee; Marion Piñeros; Malcolm Mason; Fabio Y Moraes; Wiebke Rösler; Brian Rous; Julie Torode; J Han van Krieken; Mary Gospodarowicz Journal: Nat Rev Clin Oncol Date: 2019-08-06 Impact factor: 66.675